$11.28
1.99% yesterday
Nasdaq, Apr 28, 10:00 pm CET
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Dyne Therapeutics Inc Stock price

$11.28
-0.17 1.48% 1M
-19.50 63.35% 6M
-12.28 52.12% YTD
-14.18 55.70% 1Y
+3.18 39.26% 3Y
-12.62 52.80% 5Y
-12.62 52.80% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+0.22 1.99%
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Key metrics

Market capitalization $1.28b
Enterprise Value $663.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.83
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-343.89m
Free Cash Flow (TTM) Free Cash Flow $-294.75m
Cash position $642.27m
EPS (TTM) EPS $-3.35
P/E forward negative
Short interest 15.45%
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Dyne Therapeutics Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Dyne Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 2.21 2.21
10% 10%
-
-2.21 -2.21
10% 10%
-
- Selling and Administrative Expenses 58 58
119% 119%
-
- Research and Development Expense 281 281
34% 34%
-
-342 -342
43% 43%
-
- Depreciation and Amortization 2.21 2.21
10% 10%
-
EBIT (Operating Income) EBIT -344 -344
42% 42%
-
Net Profit -317 -317
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Neutral
GlobeNewsWire
5 days ago
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people livin...
Neutral
GlobeNewsWire
14 days ago
- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driv...
Neutral
GlobeNewsWire
15 days ago
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne's Compensation Committee and made as an induce...
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 191
Founded 2017
Website www.dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today